Welcome to our dedicated page for Kintara Therapeutics news (Ticker: KTRA), a resource for investors and traders seeking the latest updates and insights on Kintara Therapeutics stock.
Kintara Therapeutics, Inc. (NASDAQ: KTRA), based in San Diego, California, is a biopharmaceutical company focused on developing novel cancer therapies to address unmet medical needs. The company's core business involves the research and development of oncology drugs that target solid tumors. Kintara is currently advancing two late-stage, Phase 3-ready therapeutics: VAL-083 and REM-001. VAL-083 is a small-molecule chemotherapeutic with a unique mechanism of action, demonstrating clinical activity against a range of cancers including glioblastoma multiforme (GBM), central nervous system cancers, ovarian cancer, and other solid tumors. On the other hand, REM-001 is a photodynamic therapy (PDT) under evaluation for cutaneous metastatic breast cancer (CMBC).
In recent developments, Kintara has received an extension from Nasdaq to regain compliance with the Listing Rule 5550(b), ensuring they meet the required financial benchmarks. The company has also partnered with Ladenburg Thalmann & Co. Inc. to explore strategic alternatives aimed at maximizing shareholder value.
Recent Projects and Financial Health
Kintara launched a new 15-patient clinical trial for REM-001 for CMBC in February 2024, funded primarily by a $2.0 million grant from the National Institutes of Health (NIH). The trial aims to optimize dosage and study design ahead of a Phase 3 initiation. Financial results for the fiscal third quarter ended March 31, 2024, reveal a cash reserve of approximately $6.35 million, reflecting strengthened financials from recent stock sales and cost-cutting initiatives.
Another significant update is Kintara's planned merger with TuHURA Biosciences, Inc., a Phase 3 immuno-oncology company. This all-stock transaction, expected to complete by Q3 2024, will result in a combined entity focused on advancing personalized cancer vaccines and bi-functional antibody drug conjugates, promising to overcome major obstacles in immunotherapy.
Conclusion
Kintara Therapeutics is dedicated to revolutionizing cancer treatment through innovative therapeutic solutions. With a robust pipeline, strategic partnerships, and a strong financial foundation, Kintara is poised to address significant gaps in cancer treatment and provide new hope to patients with limited options.
Kintara Therapeutics (Nasdaq: KTRA) reported financial results for Q3 FY2021, marking a net loss of approximately $6.6 million ($0.23 per share), an increase from $2.0 million ($0.17 per share) in Q3 FY2020. Cash and equivalents stood at $15.7 million, sufficient to fund operations into Q2 FY2022. The company initiated patient recruitment for VAL-083 in the GBM AGILE study and advanced REM-001 for Cutaneous Metastatic Breast Cancer. The financial loss reflects higher R&D expenditures and non-cash expenses from the Adgero merger.
Kintara Therapeutics (Nasdaq: KTRA), a biopharmaceutical firm specializing in cancer therapies, announced CEO Saiid Zarrabian's participation in the Benzinga Global Small Cap Conference on May 14, 2021, presenting at 12:25 PM ET. Investors can schedule one-on-one meetings post-conference. Kintara is developing two Phase 3-ready treatments: VAL-083 for glioblastoma multiforme and REM-001 for cutaneous metastatic breast cancer, with REM-001 showing an 80% complete response rate in prior trials.
Kintara Therapeutics (Nasdaq: KTRA) announced the appointment of Tamara A. Seymour to its Board of Directors, replacing John Liatos, who remains as Senior VP of Business Development. Seymour, a seasoned finance executive with over 30 years in biotech, has successfully raised over $250 million in equity and debt financing. Under her leadership, Kintara progresses its cancer therapies, VAL-083 and REM-001, targeting glioblastoma and metastatic breast cancer, respectively. The Company aims to address significant unmet medical needs in oncology.
Kintara Therapeutics (Nasdaq: KTRA) presented interim data from two Phase 2 trials of VAL-083 for glioblastoma multiforme (GBM) at the AACR Annual Meeting on April 12, 2021. The results show promising median progression-free survival (PFS) of 10.0 months in newly-diagnosed patients and 7.9 months in recurrent patients, outperforming historical controls. Both trials, conducted in Texas and China, have informed the upcoming GBM AGILE study. The most common adverse effect remains myelosuppression, with a few serious adverse events reported.
Kintara Therapeutics (Nasdaq: KTRA) announced that CEO Saiid Zarrabian will speak at the Benzinga Biotech Small Cap Conference on March 24, 2021, at 9:45 am ET. Investors can access a corporate presentation after registering for the event. Kintara focuses on developing innovative cancer therapies, including VAL-083 for glioblastoma multiforme and REM-001 for cutaneous metastatic breast cancer. Both drugs are entering late-stage clinical trials, showcasing strong clinical efficacy and safety profiles.
Kintara Therapeutics, Inc. (Nasdaq: KTRA) announced that CEO Saiid Zarrabian will participate in Maxim Group's 2021 Emerging Growth Virtual Conference on March 17-18, 2021. Zarrabian will speak on glioblastoma treatments at 9:30 am ET, with an archived replay available later. Kintara is focused on developing therapies for rare cancers, with two Phase 3-ready projects: VAL-083 for glioblastoma multiforme and REM-001 for cutaneous metastatic breast cancer. VAL-083 has shown clinical activity in various cancers, while REM-001 has an 80% complete response rate in previous studies.
Kintara Therapeutics (Nasdaq: KTRA) appointed Dr. Mario Lacouture to its REM-001 Scientific Advisory Board, focusing on Cutaneous Metastatic Breast Cancer (CMBC) as they prepare for late-stage pivotal testing of their photodynamic therapy platform, REM-001. Dr. Lacouture, a leading expert at Memorial Sloan Kettering Cancer Center, brings extensive experience in dermatologic care for cancer patients. Kintara is also advancing its VAL-083 therapy for glioblastoma multiforme (GBM) while pursuing approval for REM-001, which has shown an 80% complete response rate in previous trials.
Kintara Therapeutics (NASDAQ: KTRA) announced that its President and CEO, Saiid Zarrabian, will present at the H.C. Wainwright Global Life Sciences Conference on March 9-10, 2021. The presentation will be available on-demand from 7:00 A.M. ET on March 9 for 90 days. Kintara focuses on developing new therapies for solid tumors, currently advancing VAL-083 for glioblastoma multiforme and REM-001 for cutaneous metastatic breast cancer. VAL-083 has shown clinical activity in various cancers, while REM-001 has an 80% complete response rate in previous trials.
Kintara Therapeutics (Nasdaq: KTRA) has completed enrollment of the last patient in the recurrent arm of its Phase 2 clinical study for VAL-083, targeting glioblastoma multiforme (GBM). This trial, conducted at MD Anderson, involves 83 patients and aims to assess the efficacy of VAL-083 compared to standard treatments. The company plans to report topline results in Q2 2021. VAL-083 has shown promising median overall survival rates of 7.6 months in the recurrent group, with the drug granted Orphan Drug and Fast Track designations by the FDA.
Kintara Therapeutics (KTRA) reported its fiscal Q2 2021 results, highlighting significant advancements in its VAL-083 therapy for glioblastoma. The company entered a definitive agreement with GCAR to include VAL-083 in the GBM AGILE trial, with patient recruitment underway. Financially, Kintara showed a net loss of $5.4 million, or $0.22 per share, compared to a loss of $1.7 million in Q2 2020. Cash equivalents stood at $17.2 million, sufficient to fund operations into Q4 2021. The increased losses primarily resulted from non-cash expenses related to research and development acquisitions.
FAQ
What is the current stock price of Kintara Therapeutics (KTRA)?
What is the market cap of Kintara Therapeutics (KTRA)?
What is the primary focus of Kintara Therapeutics?
What are Kintara's main therapeutic programs?
Where is Kintara Therapeutics based?
What recent financial developments has Kintara announced?
What strategic alternatives is Kintara exploring?
What is the significance of the REM-001 clinical trial?
Has Kintara received any grants for their clinical trials?
What is VAL-083 and what cancers does it target?
How is Kintara ensuring compliance with Nasdaq listing rules?
What potential benefits are expected from the merger with TuHURA Biosciences?
